[Leu15]-Gastrin I amide (human) (trifluoroacetate salt) (Synonyms: 15-Leu-Gastrin-17) |
Catalog No.GC46361
One-Click Copy Product Info
|
Gastrin is gastrointestinal hormones which is structurally similar in carboxy-terminal amino acids.
Products are for research use only. Not for human use. We do not sell to patients.
![[Leu15]-Gastrin I amide (human) (trifluoroacetate salt) Chemical Structure](/media/struct/GC4/GC46361.png "[Leu15]-Gastrin I amide (human) (trifluoroacetate salt) Chemical Structure")
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Gastrin is gastrointestinal hormones which is structurally similar in carboxy-terminal amino acids[1]. Gastrin are normally produced at high levels by endocrine (G) cells located in the gastric antrum and proximal duodenal mucosa. Gastrin can activate through the CCK2R several signaling pathways that have been linked to proliferation, cell adhesion, and antiapoptotic effects[2]. Human [Leu15]-gastrin-17 is a synthetic analogue of human gastrin-17 and is considered more stable than natural human [Met15]-gastrin-17 while having the same bioactivity[3]
[Leu15]-Gastrin Ⅰ can be synthesized use the Clt-resin[4]. Gastrin analogues can be hydrolyzed by angiotensin-converting enzyme(ACE), indicated that it is possible that administration of ACE inhibitors, used clinically as antihypertensive drugs, could affect the metabolism of gastrin fragments in vivo[5]
Human [Leu15]-gastrin Ⅰ directly modulated secretin binding to its receptors, that may involve in the inhibitory action of secretin on acid secretion induced by gastrin[1]. Continuous infusion of human [Leu15]-gastrin-17 via osmotic minipumps increased the plasma levels of gastrin. In the rats given the high dose(2.4nmol/kg∙h) of human [Leu15]-gastrin-17, the ECL-cell density, the mucosal histamine concentration and HDC activity increased significantly[3]. Continuous infusion of human [Leu15]-gastrin-17(5nmol/kg∙h) for 6 days induces hypergastrinaemia, and caused both vacuoles and lipofuscin bodies to appear in large numbers, suggesting that gastrin stimulates the development not only of vacuoles but also of lipofuscin, perhaps through enhanced autophagocytosis and/or oxidative stress[6]
References:
[1]. Iwakawa S, Nomura H, et al. Direct modulation of secretin binding sites by gastrin in the rat stomach. J Pharmacobiodyn. 1992;15(8):437-441.
[2].Ferrand A, Wang TC. Gastrin and cancer: a review. Cancer Lett. 2006;238(1):15-29.
[3].Ryberg B, Axelson J, et al. Trophic effects of continuous infusion of [Leu15]-gastrin-17 in the rat. Gastroenterology. 1990;98(1):33-38.
[4].Barlos K, Gatos D, et al. Application of 2-chlorotrityl resin in solid phase synthesis of (Leu15)-gastrin I and unsulfated cholecystokinin octapeptide. Selective O-deprotection of tyrosine. Int J Pept Protein Res. 1991;38(6):555-561.
[5].Dubreuil P, Fulcrand P, et al. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide. Biochem J. 1989;262(1):125-130.
[6]. Zhao CM, Chen D, et al. ECL cells of the rat stomach: development of lipofuscin in response to sustained gastrin stimulation. Cell Tissue Res. 1998;291(2):315-323.
| Cell experiment [1]: | |
|
Preparation Method |
Enzymic hydrolyses of gastrin analogues were analysed by HPLC Enzyme (0.005 unit) was incubated with substrate (0.1mM) and buffer in a final volume of 0.1mL. Buffer was 100mM-Tris/HCl, pH7.5, containing 0.3M-NaCl. When specific inhibitors of ACE were used, they were preincubated with the enzyme for 5-15min at 37℃. Reactions were carried out at 37℃ for various times and then stopped by freezing in liquid nitrogen. Samples (20μL) were stored at -80℃ before HPLC analysis. In kinetic studies, ACE (0.005 unit) was incubated with gastrin analogues at ten different substrate concentrations (ranging from 10 to 1000μM), in a buffer containing 300mM-NaCl. |
|
Reaction Conditions |
10 to 1000μM |
|
Applications |
The initial and major site of hydrolysis was the penultimate peptide bond, which generated a major product, the C-terminal amidated dipeptide Asp-Phe-NH2. As a secondary cleavage, ACE subsequently released di- or tri-peptides from the C-terminal end of the remaining N-terminal fragments. Hydrolysis of [Leu15]-gastrin-(14-17)-peptide in the presence of ACE was dependent on the chloride-ion concentration. Km values for the hydrolysis of [Leu15]-gastrin-(11-17)-peptide and [Leu15]-gastrin-(14-17)-peptide at an NaCl concentration of 300mm were respectively 420 and 3280μM, and the catalytic constants were about 115 and 885min-1. The kcat /Km for the reactions at 37℃ was approx. 0.28μM-1min-1. These results suggest that ACE might be involved in the metabolism in vivo of gastrin short fragments. |
| Animal experiment [2]: | |
|
Animal models |
Sprague-Dawley rats, weighing 200±225g |
|
Preparation Method |
Sprague-Dawley rats were given continuous subcutaneous infusion of human [Leu15]-gastrin-17 (5nmol/kg∙h) via osmotic minipumps, implanted in the neck under anaesthesia for 1, 2 or 6 days |
|
Dosage form |
5nmol/kg∙h |
|
Applications |
Hypergastrinaemia was induced by continuous infusion of human [Leu15]-gastrin-17 for 6 days. The treatment caused both vacuoles and lipofuscin bodies to appear in large numbers and the vacuoles disappeared promptly after interruption of the hypergastrinaemia, whereas the lipofuscin bodies remained. |
|
References: [1]. Dubreuil P, Fulcrand P, et al. Novel activity of angiotensin-converting enzyme. Hydrolysis of cholecystokinin and gastrin analogues with release of the amidated C-terminal dipeptide. Biochem J. 1989;262(1):125-130. [2]. Zhao CM, Chen D, et al. ECL cells of the rat stomach: development of lipofuscin in response to sustained gastrin stimulation. Cell Tissue Res. 1998;291(2):315-323. |
|
| Cas No. | N/A | SDF | |
| Synonymes | 15-Leu-Gastrin-17 | ||
| Chemical Name | 5-oxo-L-prolylglycyl-L-prolyl-L-tryptophyl-L-leucyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-α-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-leucyl-L-α-aspartyl-L-phenylalaninamide, trifluoroacetate salt | ||
| Canonical SMILES | NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@H](CC(C)C)NC([C@@H](NC(CNC([C@@H](NC([C@H](C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC(C)C)NC([C@@H](NC([C@@H]2CCCN2C(CNC([C@@H](N3)CCC3=O)=O)=O)=O)CC4=CNC5=C4C=CC=C5)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)=O)CC6=CC=C(C=C6)O)=O)=O)CC7=CNC8=C7C=CC=C8)=O)=O)CC(O)=O)=O)=O.FC(F)(C(O)=O)F | ||
| Formula | C98H126N20O31.XCF3COOH | M.Wt | 2080.2 |
| Solubility | 0.1 M NaOH: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 480.7 μL | 2.4036 mL | 4.8072 mL |
| 5 mM | 96.1 μL | 480.7 μL | 961.4 μL |
| 10 mM | 48.1 μL | 240.4 μL | 480.7 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)